PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Biomedical Advanced Research and Development Authority (BARDA), Office of Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, DC.\', \'The Janssen Pharmaceutical Companies of Johnson & Johnson, Spring House, PA.\', \'Foundation for the National Institutes of Health, North Bethesda, MD.\', \'National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD.\', \'National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.\', \'Novartis Pharma AG, Basel, Switzerland.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1097/CCM.0000000000005295
?:hasPublicationType
?:journal
  • Critical care medicine
is ?:pmid of
?:pmid
?:pmid
  • 34495876
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 3.116
?:rankingScore_hIndex
  • 246
?:title
  • Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines-Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34495876>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34495876>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all